Prana’s Huntington Disease trial analysis to feature at global movement disorder conference
Prana is pleased to announce that further analysis of the results of its REACH2HD trial will be featured at the 20th Annual International Movement Disorder Society Congress.
Prana receives $6.5 million R&D Tax Incentive Refund
Prana has today announced that is has received a A$6.5 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
Prana Presents at World Orphan Drug Congress
Prana presents unique drug platform at World Orphan Drug Congress
Prana Maintains NASDAQ Listing
Prana regains compliance with NASDAQ continued listing requirements and continues to work towards FDA submission
Prana Biotechnology AGM Presentation
Prana AGM Webcast Details
Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) will host a webcast of its Annual General Meeting on Friday, November 13, 2015, at 9.30am AEDT.
Preliminary Final Report (Appendix 4E)
Prana Biotechnology Limited has released its Preliminary Final Report (Appendx 4E) for the 2014-15 financial year.
Prana reports FY15 financial results
Prana Biotechnology yesterday announced its financial results for the 12 months to June 30, 2015.
Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial
Prana Biotechnology has today announced the safety outcomes of the IMAGINE Extension study in patients with Alzheimer’s disease. A 250mg dose of PBT2 was safe and well tolerated over a 2 year period. The independent Data Safety Monitoring Board did not identify any safety concerns related to PBT2.